Veige Healthcare
The new standard in women’s healthcare
The Need
An estimated 32 million women in the USA alone suffer from VVA, an acutely painful condition affecting vaginal and vulval tissue. The FDA has deemed that all currently approved estrogen products require a “Black Box” warning regarding cardiovascular and cancer risks. We are developing an alternative that is effective and safe. Women’s healthcare is changing, now.
The Solution
Currently, the only approved treatment available to treat this serious problem is Hormone Replacement Therapy (HRT). HRT is helpful in reducing VVA symptoms in about 75% of PM patients; approximately 25% of women are non-responders.
The FDA has determined that HRT also causes a significant increase in the incidence of cardiac events, dementia, stroke, deep vein thrombosis and cancer, requiring a Black Box warning label on all estrogen-containing products, emphasizing the significant health risks. Veige has a completely novel treatment for VVA, which has an efficacy profile similar to that of
estrogen therapy without the associated health risks.
Veige offers a completely novel treatment for VVA, IZN-6NVS, which has an efficacy profile similar to that of estrogen therapy, without the associated health risks. This topically applied treatment is based on many years of research into the biologically active components, found in specific botanicals, that have been patented and combined in a formulation designed to maximize the therapeutic effect while ensuring a strong safety profile.
​
A successful clinical trial investigated the efficacy and safety of Veige in symptomatic VVA. Veige is the only non-estrogen product that will actually repair the vaginal tissue, providing a comprehensive reduction of symptoms AND a return of vaginal health. Veige rapidly reduced symptoms and demonstrated full repair of the vaginal protective epithelium.
Veige not only has a lubricating and moisturizing effect, but the unique botanical preparation, combined with the proprietary formulation creates a synergistic benefit that actually heals and restores the vaginal tissue to health. The Veige clinical trial demonstrated a therapeutic effect comparable to that of estrogen without side effects, making the product safe for long-term use.
Pathway to Market FDA Clearance
The Veige product for the VVA indication is expected to be cleared as a Medical Device via the 510(k) FDA registration process. Veige has sufficient robust clinical trial data to support strong claims and product differentiation. Time projection for completion of this FDA clearance is Q3 2025. In addition, Veige is planning an additional trial, post-FDA clearance, to enhance therapeutic claims and strengthen the professional acceptance of this product.
Team
Jonathan Kalman, CEO
Serial entrepreneur, with track record of launching, building, and selling successful businesses.
-
Early investor and board member across early-stage technology companies with a focus on biopharma and medical devices.
-
Three successful M&A transactions to international corporations for amounts ranging from $70M to $1.1BB.
Dr. William Levine, CSO
-
DDS degree with specialty training in Periodontics from Columbia University.
-
Founder of Izun Pharmaceuticals, a biopharmaceutical company specializing in Botanical Medicine.
-
Diplomate of the American Board of Periodontology.
-
Member of Scientific Board of companies focused on Robotic Surgery and Oral Diagnostic technologies.
Les Kraus, CFO
-
CPA with 40+ years of operational and financial experience covering industrial, retail and wholesale businesses.
-
Former CFO of Australia’s largest menswear retailer, where he managed two sale processes to private equity firms.
Dr Amy Rosenbluh, Director of Production & Laboratory Manager
-
Master’s degree from Harvard University and Ph.D. from Tel Aviv University, with post-doctoral fellowships at both Stanford University and the Weizmann Institute.
-
Vast experience in academic research and management, both in academia and in the private sector.
Scientific Advisory Board
Robin Kroll, MD
Dr. Kroll is a recognized leader in women's healthcare. She is a board-certified Gynecologist and Menopause Clinician with special interests in contraception, menopause, and sexual dysfunction. She is Medical Director Emeritus of Women’s Clinical Research Center where she now serves as Consultant/Advisor. Dr. Kroll is a member of numerous professional societies and has been selected by her peers to be included in Best Doctors and has been named in “Top Doctors” by Seattle Magazine. Dr. Kroll has served as a principal investigator for over 300 clinical trials in the field of women’s health and publishes frequently in peer reviewed journals.
​
Dr. Brian Bernick
Dr. Bernick is a multidimensional healthcare executive and entrepreneur with 30 years of clinical medicine experience, primarily in women’s health. Dr. Bernick founded a women’s health company responsible for 3 FDA new drug approvals and a pharmaceutical company exclusively committed to advancing the health of women. Dr. Bernick is recognized by colleagues as one of the leading practitioners of obstetrics & gynecology and has over 100 peer- reviewed publications and presentations of original research and over 70 US and foreign patents focusing on drug therapies and analysis.
​
Prof. Gabriel Nussbaum
​Prof. Nussbaum is a physician researcher and a tenured full professor in the Institute for Biomedical and Oral Research of the Hebrew University of Jerusalem. He began his research career as an MD, PhD student at the Albert Einstein College of Medicine and did his postdoctoral work at the Weizmann Institute of Science. Prof. Nussbaum trained in internal medicine and conducts research at the interface of inflammation, the host response to microbial pathogens, and cancer.
Contact us
Corporate Headquarters
1177 6th Avenue
5th floor
New York, NY 10036
1-800-580-4387
R&D Headquarters
11 Kiryat Mada Street
3rd floor
Har Hotzvim, Jerusalem 9777611
972-72-245-8950